Could a drug calm this rare muscle and lung disease?
NCT ID NCT07377058
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests whether tocilizumab, a drug that blocks inflammation, can improve symptoms and breathing in adults with anti-MDA5+ dermatomyositis, a rare autoimmune disease affecting muscles, skin, and lungs. About 110 participants will receive either tocilizumab or a placebo every two weeks for two months. Researchers will track symptom improvement and lung function changes.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
tocilizumab (a drug that blocks IL-6, given as an infusion every two weeks)
What this could lead to
If it works, this could point toward a new treatment option for anti-MDA5+ dermatomyositis, especially for lung problems.
What could go wrong
This is an early-phase trial with only 110 people, so results may not apply to everyone. The drug may not work better than placebo, and side effects like infections are possible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DERMATOMYOSITIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Peking Union Medical College Hospital
RECRUITINGBeijing, Beijing Municipality, China
Contact Phone: •••-•••-•••• Email: •••••@•••••